Stefan Kolb

Stefan Kolb has extensive work experience in the field of medical affairs and scientific affairs. Stefan is currently the Vice President of Scientific Affairs at Zevra Therapeutics, where they have been working since December 2022. Prior to this, they served as the Senior Global Medical Director of Medical Affairs at Zevra Therapeutics from June 2022 to November 2022.

Before joining Zevra Therapeutics, Stefan was the Founder of Curaxon Ltd starting from April 2020. Stefan also worked at Orphazyme A/S as the Senior Global Medical Director of Lysosomal Storage Diseases from February 2020 to May 2022.

From 2017 to 2019, Stefan worked at Janssen Pharmaceutical - Johnson & Johnson as the Senior Global Medical Director of Specialty Care. Prior to this, they held various roles at Actelion, including Senior Global Medical Director of Specialty Care, Senior Global Medical Director, and Global Medical Director. At Actelion, they focused on inborn metabolic and neurodegenerative disorders, particularly lysosomal storage diseases.

Stefan's career began at Pfizer, where they served as the European Medical Manager of Neuroscience and Medical Advisor for CNS & Endocrine Care from 2001 to 2008. Before joining Pfizer, they worked at University Hospital Zurich and the University of Zurich in research and laboratory positions.

Overall, Stefan Kolb has demonstrated expertise in medical and scientific affairs, particularly in the areas of CNS, genetics, neurology, and pediatrics. Stefan has a strong background in lysosomal storage diseases and has held leadership positions in various pharmaceutical companies.

Stefan Kolb obtained their Doctor of Medicine (MD) degree from the University of Zurich between 1987 and 1992. Stefan'sfield of study was Medicine.